Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

492
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
492
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

319
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
319
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

268
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
268
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

855
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
855
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

599
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
599

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble Programmed Death-1 as a Biomarker of Severity and Progression in Nodular-bronchiectatic Nontuberculous Mycobacterial Pulmonary Disease: A Multicountry Validation Cohort Study.

Archivos de bronconeumologia·2026
Same author

Effectiveness of conventional antimicrobial agents against carbapenem resistant non-carbapenem β-lactams susceptible Pseudomonas aeruginosa infection in critically ill patients: a multicentre retrospective study.

BMC infectious diseases·2026
Same author

Ventilator-derived <i>Versus</i> Standard Rapid Shallow Breathing Index for Weaning Assessment: A Systematic Review.

In vivo (Athens, Greece)·2026
Same author

Association of body morphotypes with disease severity and its dynamic changes following treatment in patients with nontuberculous mycobacterial lung disease: a sex-stratified analysis.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2026
Same author

Immune Microenvironment and Genetic Signatures of End-Stage Renal Disease and Their Association with Sepsis: Insights from Public Transcriptomic Data and a Multicenter Clinical Cohort.

Biomedicines·2026
Same author

Triggering Receptor Expressed on Myeloid Cells-2 Regulates Innate Lymphoid Cell Levels in Bleomycin-Induced Pulmonary Fibrosis.

The Kaohsiung journal of medical sciences·2026

Related Experiment Video

Updated: Nov 16, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K

Statin use and impact on tuberculosis risk.

Vincent Yi-Fong Su1,2,3, Sheng-Wei Pan2,3, Yung-Feng Yen1,2

  • 1Department of Internal Medicine, Taipei City Hospital, Taipei, Taiwan.

Expert Review of Anti-Infective Therapy
|March 1, 2021
PubMed
Summary

Statins may help treat tuberculosis (TB) by lowering cholesterol, which Mycobacterium tuberculosis needs to survive. Further research is needed to confirm statins

Keywords:
HMG-CoA reductase inhibitorMycobacterium tuberculosisdiabetes mellitusmetforminpneumoniastatintuberculosis

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.9K

Related Experiment Videos

Last Updated: Nov 16, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.0K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.0K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.9K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major global health threat.
  • Current TB treatment involves prolonged (6-9 months) antimicrobial therapy.
  • MTB utilizes host macrophage cholesterol for infection and survival.

Purpose of the Study:

  • To review recent studies on statins' effects in preventing or treating TB.
  • To explore statins as a potential adjunct therapy to shorten TB treatment duration.
  • To investigate statins' role in enhancing host immune response against MTB.

Main Methods:

  • Narrative review of existing scientific literature.
  • Analysis of studies investigating the impact of statins on TB infection.
  • Examination of cholesterol's role in MTB pathogenesis and statin's mechanism of action.

Main Results:

  • Statins inhibit cholesterol synthesis, potentially reducing MTB's survival advantage.
  • Evidence suggests a possible benefit of statins in managing TB infections.
  • Cholesterol reduction by statins is linked to improved outcomes in other infectious diseases.

Conclusions:

  • Published evidence indicates statins may offer therapeutic benefits for TB patients.
  • Further research should explore the efficacy of different statin types in TB treatment.
  • Investigating statins' impact on host immunity against MTB is warranted.